These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

119 related articles for article (PubMed ID: 36222504)

  • 41. Tall cell carcinoma with reversed polarity of breast: Sonographic and magnetic resonance imaging findings.
    Lee NY; Chang YW; Lee EJ; Jin YM
    J Clin Ultrasound; 2023 Mar; 51(3):494-497. PubMed ID: 35904337
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Breast Tumor Resembling the Tall Cell Variant of Papillary Thyroid Carcinoma: Molecular Characterization by Next-Generation Sequencing and Histopathological Comparison With Tall Cell Papillary Carcinoma of Thyroid.
    Zhong E; Scognamiglio T; D'Alfonso T; Song W; Tran H; Baek I; Hoda SA
    Int J Surg Pathol; 2019 Apr; 27(2):134-141. PubMed ID: 30227763
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Molecular alterations of isocitrate dehydrogenase 1 and 2 (IDH1 and IDH2) metabolic genes and additional genetic mutations in newly diagnosed acute myeloid leukemia patients.
    Chotirat S; Thongnoppakhun W; Promsuwicha O; Boonthimat C; Auewarakul CU
    J Hematol Oncol; 2012 Mar; 5():5. PubMed ID: 22397365
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Functional alteration of canine isocitrate dehydrogenase 2 (IDH2) via an R174K mutation.
    Kawakami S; Ochiai K; Kato Y; Michishita M; Hirama H; Obara R; Azakami D; Watanabe M; Omi T
    J Vet Med Sci; 2018 Jan; 80(1):85-91. PubMed ID: 29162772
    [TBL] [Abstract][Full Text] [Related]  

  • 45. The prognostic impact and stability of Isocitrate dehydrogenase 2 mutation in adult patients with acute myeloid leukemia.
    Chou WC; Lei WC; Ko BS; Hou HA; Chen CY; Tang JL; Yao M; Tsay W; Wu SJ; Huang SY; Hsu SC; Chen YC; Chang YC; Kuo KT; Lee FY; Liu MC; Liu CW; Tseng MH; Huang CF; Tien HF
    Leukemia; 2011 Feb; 25(2):246-53. PubMed ID: 21079611
    [TBL] [Abstract][Full Text] [Related]  

  • 46. IDH1/2 gene hotspot mutations in central nervous system tumours: analysis of 922 Chinese patients.
    Chen N; Yu T; Gong J; Nie L; Chen X; Zhang M; Xu M; Tan J; Su Z; Zhong J; Zhou Q
    Pathology; 2016 Dec; 48(7):675-683. PubMed ID: 27780605
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Clinico-neuropathological features of isocitrate dehydrogenase 2 gene mutations in lower-grade gliomas.
    Wang LM; Li Z; Piao YS; Cai YN; Zhang LY; Ge HJ; Xu WW; Lu DH
    Chin Med J (Engl); 2019 Dec; 132(24):2920-2926. PubMed ID: 31833906
    [TBL] [Abstract][Full Text] [Related]  

  • 48. IDH2 Mutation Analysis in Undifferentiated and Poorly Differentiated Sinonasal Carcinomas for Diagnosis and Clinical Management.
    Riobello C; López-Hernández A; Cabal VN; García-Marín R; Suárez-Fernández L; Sánchez-Fernández P; Vivanco B; Blanco V; López F; Franchi A; Llorente JL; Hermsen MA
    Am J Surg Pathol; 2020 Mar; 44(3):396-405. PubMed ID: 31876581
    [TBL] [Abstract][Full Text] [Related]  

  • 49. IDH2 mutation in gliomas including novel mutation.
    Koh J; Cho H; Kim H; Kim SI; Yun S; Park CK; Lee SH; Choi SH; Park SH
    Neuropathology; 2015 Jun; 35(3):236-44. PubMed ID: 25495392
    [TBL] [Abstract][Full Text] [Related]  

  • 50. IDH1 and IDH2 mutations are frequent genetic alterations in acute myeloid leukemia and confer adverse prognosis in cytogenetically normal acute myeloid leukemia with NPM1 mutation without FLT3 internal tandem duplication.
    Paschka P; Schlenk RF; Gaidzik VI; Habdank M; Krönke J; Bullinger L; Späth D; Kayser S; Zucknick M; Götze K; Horst HA; Germing U; Döhner H; Döhner K
    J Clin Oncol; 2010 Aug; 28(22):3636-43. PubMed ID: 20567020
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Immunohistochemistry using monoclonal antibody MsMab-2 is useful to detect IDH1 R132L in intrahepatic cholangiocarcinoma.
    Hayashi A; Misumi K; Shibahara J; Kokudo N; Kato Y; Fukayama M
    Pathol Int; 2016 Oct; 66(10):578-582. PubMed ID: 27595804
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Multi-specific monoclonal antibody MsMab-2 recognizes IDH1-R132L and IDH2-R172M mutations.
    Ogasawara S; Kaneko MK; Tsujimoto Y; Liu X; Kato Y
    Monoclon Antib Immunodiagn Immunother; 2013 Dec; 32(6):377-81. PubMed ID: 24328739
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Diagnostic testing for IDH1 and IDH2 variants in acute myeloid leukemia an algorithmic approach using high-resolution melting curve analysis.
    Patel KP; Barkoh BA; Chen Z; Ma D; Reddy N; Medeiros LJ; Luthra R
    J Mol Diagn; 2011 Nov; 13(6):678-86. PubMed ID: 21889610
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Oncogenetic landscape and clinical impact of IDH1 and IDH2 mutations in T-ALL.
    Simonin M; Schmidt A; Bontoux C; Dourthe MÉ; Lengliné E; Andrieu GP; Lhermitte L; Graux C; Grardel N; Cayuela JM; Huguet F; Arnoux I; Ducassou S; Macintyre E; Gandemer V; Dombret H; Petit A; Ifrah N; Baruchel A; Boissel N; Asnafi V
    J Hematol Oncol; 2021 May; 14(1):74. PubMed ID: 33941203
    [TBL] [Abstract][Full Text] [Related]  

  • 55. IDH2 inhibition in AML: Finally progress?
    Stein EM
    Best Pract Res Clin Haematol; 2015; 28(2-3):112-5. PubMed ID: 26590767
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Reductive carboxylation and 2-hydroxyglutarate formation by wild-type IDH2 in breast carcinoma cells.
    Smolková K; Dvořák A; Zelenka J; Vítek L; Ježek P
    Int J Biochem Cell Biol; 2015 Aug; 65():125-33. PubMed ID: 26007236
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Genomic Profiling Identifies Association of
    Zhu GG; Nafa K; Agaram N; Zehir A; Benayed R; Sadowska J; Borsu L; Kelly C; Tap WD; Fabbri N; Athanasian E; Boland PJ; Healey JH; Berger MF; Ladanyi M; Hameed M
    Clin Cancer Res; 2020 Jan; 26(2):419-427. PubMed ID: 31615936
    [TBL] [Abstract][Full Text] [Related]  

  • 58. IDH1/2 Mutations in Sinonasal Undifferentiated Carcinomas : Previously Undescribed IDH2 R172K and R140x Variants.
    Kakkar A; Rathor A; Ashraf SF; Singh V; Sikka K; Jain D
    Am J Surg Pathol; 2022 Sep; 46(9):1284-1290. PubMed ID: 35486703
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Leukemic mutations in the methylation-associated genes DNMT3A and IDH2 are rare events in pediatric AML: a report from the Children's Oncology Group.
    Ho PA; Kutny MA; Alonzo TA; Gerbing RB; Joaquin J; Raimondi SC; Gamis AS; Meshinchi S
    Pediatr Blood Cancer; 2011 Aug; 57(2):204-9. PubMed ID: 21504050
    [TBL] [Abstract][Full Text] [Related]  

  • 60. IDH1 and IDH2 mutations are frequent events in central chondrosarcoma and central and periosteal chondromas but not in other mesenchymal tumours.
    Amary MF; Bacsi K; Maggiani F; Damato S; Halai D; Berisha F; Pollock R; O'Donnell P; Grigoriadis A; Diss T; Eskandarpour M; Presneau N; Hogendoorn PC; Futreal A; Tirabosco R; Flanagan AM
    J Pathol; 2011 Jul; 224(3):334-43. PubMed ID: 21598255
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.